JP2014521958A - 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法 - Google Patents

胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法 Download PDF

Info

Publication number
JP2014521958A
JP2014521958A JP2014523039A JP2014523039A JP2014521958A JP 2014521958 A JP2014521958 A JP 2014521958A JP 2014523039 A JP2014523039 A JP 2014523039A JP 2014523039 A JP2014523039 A JP 2014523039A JP 2014521958 A JP2014521958 A JP 2014521958A
Authority
JP
Japan
Prior art keywords
fluid
cells
cancer
ligand
intrathoracic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521958A5 (enExample
Inventor
アルベルダ，ステイーブン・エム
シユエド，ダニエル
ラオ，ガラ・チヤンドラ
コネリー，マーク
フアウルク，ブラド
Original Assignee
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
ベリデツクス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア, ベリデツクス・エルエルシー filed Critical ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Publication of JP2014521958A publication Critical patent/JP2014521958A/ja
Publication of JP2014521958A5 publication Critical patent/JP2014521958A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
JP2014523039A 2011-07-28 2012-07-27 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法 Pending JP2014521958A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512576P 2011-07-28 2011-07-28
US61/512,576 2011-07-28
PCT/US2012/048452 WO2013016600A2 (en) 2011-07-28 2012-07-27 Methods and reagents for diagnosing conditions and characterization of tumor cells associated with serous fluids

Publications (2)

Publication Number Publication Date
JP2014521958A true JP2014521958A (ja) 2014-08-28
JP2014521958A5 JP2014521958A5 (enExample) 2015-09-03

Family

ID=46650901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523039A Pending JP2014521958A (ja) 2011-07-28 2012-07-27 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法

Country Status (6)

Country Link
US (1) US20140295426A1 (enExample)
EP (1) EP2737317A2 (enExample)
JP (1) JP2014521958A (enExample)
IL (1) IL230687A0 (enExample)
TW (1) TW201312117A (enExample)
WO (1) WO2013016600A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6238856B2 (ja) * 2014-08-25 2017-11-29 シスメックス株式会社 尿中異型細胞の分析方法、尿分析装置および体液中異型細胞の分析方法
CA3000438C (en) * 2015-09-28 2024-05-14 The Governing Council Of The University Of Toronto Device for magnetic profiling of particles in a flow
US10696961B2 (en) 2017-12-01 2020-06-30 Global Life Sciences Solutions Usa Llc Magnetic cell isolation techniques
CA3082861A1 (en) * 2017-12-01 2019-06-06 General Electric Company Methods for cell enrichment and isolation
EP4073511A4 (en) * 2019-12-12 2024-01-17 University of Miami MATERIALS AND METHODS FOR DETECTING EXTRACELLULAR VESICLES
EP4139440B1 (en) 2020-04-22 2026-08-19 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2021226061A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4146793A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2024501452A (ja) 2020-12-11 2024-01-12 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｂｒａｆ阻害剤及び／またはｍｅｋ阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
JP2023554395A (ja) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
JP2024501845A (ja) 2020-12-31 2024-01-16 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
JP2024509184A (ja) 2021-03-05 2024-02-29 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍保存及び細胞培養組成物
TW202304480A (zh) 2021-03-19 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
EP4314253A2 (en) 2021-03-25 2024-02-07 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
AU2022263418A1 (en) 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
US20240269180A1 (en) 2021-05-17 2024-08-15 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3226942A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3231018A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
US20250000903A1 (en) 2021-09-24 2025-01-02 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
US20230187042A1 (en) 2021-10-27 2023-06-15 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
JP2025503987A (ja) 2022-01-28 2025-02-06 アイオバンス バイオセラピューティクス，インコーポレイテッド ペイロードを発現するように操作された腫瘍浸潤リンパ球
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4612277A1 (en) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
IL325907A (en) 2023-07-13 2026-03-01 Iovance Biotherapeutics Inc Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
IL328125A (en) 2023-11-06 2026-06-01 Iovance Biotherapeutics Inc Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
WO2026050217A2 (en) 2024-08-27 2026-03-05 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63109793A (ja) * 1986-10-28 1988-05-14 Kyowa Hakko Kogyo Co Ltd 抗ヒト中皮細胞単クロ−ン性抗体
JPH09510779A (ja) * 1994-03-10 1997-10-28 フォドスタッド オイステイン 特定化あるいは混合した細胞母集団または混合細胞母集団を含む溶液内の特定標的細胞を検出する方法および装置
JP2008538509A (ja) * 2005-04-21 2008-10-30 カリフォルニア インスティチュート オブ テクノロジー パリレンメンブレンフィルターの使用
JP2009525478A (ja) * 2006-01-31 2009-07-09 ビオメリュー 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
JP2010501549A (ja) * 2006-08-23 2010-01-21 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 胆管癌治療用薬学的組成物、胆管癌の成長または浸潤抑制方法、および胆管癌の治療方法
WO2010102177A1 (en) * 2009-03-06 2010-09-10 Becton, Dickinson And Company Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
CA2065874C (en) 1989-09-15 2001-12-11 Joseph P. Brown Hybridoma ct43 producing a monoclonal antibody to a mucin epitope of colorectal cancer
CA2144750A1 (en) 1992-09-17 1994-03-31 Rolf Stahel Tumor-specific antibodies and antigen
US6660159B1 (en) 1996-06-07 2003-12-09 Immunivest Corporation Magnetic separation apparatus and methods
US6136182A (en) 1996-06-07 2000-10-24 Immunivest Corporation Magnetic devices and sample chambers for examination and manipulation of cells
AU3374597A (en) 1996-06-07 1998-01-05 Immunivest Corporation Magnetic separation employing external and internal gradients
US6790366B2 (en) 1996-06-07 2004-09-14 Immunivest Corporation Magnetic separation apparatus and methods
US6890426B2 (en) 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
WO1999041613A1 (en) 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US7282350B2 (en) 1998-02-12 2007-10-16 Immunivest Corporation Labeled cell sets for use as functional controls in rare cell detection assays
US6623982B1 (en) 1999-07-12 2003-09-23 Immunivest Corporation Increased separation efficiency via controlled aggregation of magnetic nanoparticles
JP3766064B2 (ja) 2001-02-12 2006-04-12 イムニベスト・コーポレイション 光学分析用の標本試料を収容するためのカートリッジ
WO2003019141A2 (en) * 2001-08-23 2003-03-06 Immunivest Corporation Analysis of circulating tumor cells, fragments, and debris
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
EP1723428A2 (en) * 2004-02-19 2006-11-22 Yale University Corporation Identification of cancer protein biomarkers using proteomic techniques
US20060024824A1 (en) * 2004-07-16 2006-02-02 Steven Woodside Magnetic cell separation method
US7846743B2 (en) * 2005-04-21 2010-12-07 California Institute Of Technology Uses of parylene membrane filters
EP2037265A1 (en) * 2007-09-17 2009-03-18 Adnagen AG Solid phase cell isolation and/or enrichment method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63109793A (ja) * 1986-10-28 1988-05-14 Kyowa Hakko Kogyo Co Ltd 抗ヒト中皮細胞単クロ−ン性抗体
JPH09510779A (ja) * 1994-03-10 1997-10-28 フォドスタッド オイステイン 特定化あるいは混合した細胞母集団または混合細胞母集団を含む溶液内の特定標的細胞を検出する方法および装置
JP2008538509A (ja) * 2005-04-21 2008-10-30 カリフォルニア インスティチュート オブ テクノロジー パリレンメンブレンフィルターの使用
JP2009525478A (ja) * 2006-01-31 2009-07-09 ビオメリュー 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
JP2010501549A (ja) * 2006-08-23 2010-01-21 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 胆管癌治療用薬学的組成物、胆管癌の成長または浸潤抑制方法、および胆管癌の治療方法
WO2010102177A1 (en) * 2009-03-06 2010-09-10 Becton, Dickinson And Company Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC KIELHORN: "USE OF MAGNETIC ENRICHMENT FOR DETECTION OF CARCINOMA CELLS IN FLUID SPECIMENS", CANCER, vol. V94 N1, JPN5015000886, 1 January 2002 (2002-01-01), pages 205 - 211, ISSN: 0003313015 *
MASAHIRO HORIKAWA, ONCOLOGY REPORTS, vol. V25 N5, JPN5015000877, 18 February 2011 (2011-02-18), pages 1413 - 1420, ISSN: 0003313016 *

Also Published As

Publication number Publication date
EP2737317A2 (en) 2014-06-04
WO2013016600A2 (en) 2013-01-31
US20140295426A1 (en) 2014-10-02
WO2013016600A3 (en) 2013-04-18
IL230687A0 (en) 2014-03-31
TW201312117A (zh) 2013-03-16

Similar Documents

Publication Publication Date Title
US20140295426A1 (en) Methods for Diagnosing Cancer by Characterization of Tumor Cells Associated with Pleural or Serous Fluids
JP5479355B2 (ja) 血液中の循環黒色腫細胞の自動計数及び特徴付け
JP4593557B2 (ja) 循環腫瘍細胞（ｃｔｃ）：転移癌患者における増悪までの時間、生存および療法に対する応答の早期評価
US20140113310A9 (en) Cancer detection markers
US20070154960A1 (en) Method for assessing disease states by profile analysis of isolated circulating endothelial cells
WO2010065968A1 (en) Cancer detection markers
JP2008533487A (ja) 循環腫瘍細胞を用いる転移性乳癌患者の療法中の各追跡期間ポイントでの無増悪および全生存を予測する方法
US20080113350A1 (en) Blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (FISH)
JP2024023284A (ja) がんのスクリーニング、診断、治療、及び再発における巨細胞の核酸の特徴付けの使用方法
Quirós‐Caso et al. Routine flow cytometry approach for the evaluation of solid tumor neoplasms and immune cells in minimally invasive samples
KR20190045200A (ko) 방광암용 바이오마커로서의 케라틴 17
EP2450457A1 (en) Method of analyzing genetically abnormals cells
WO2005116264A2 (en) A blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (fish)
Tkaczuk et al. The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method
JP6707505B2 (ja) 腫瘍細胞を検出するためのステロイド受容体アッセイ
WO2022030626A1 (ja) 膀胱癌診断方法
JP2012022002A (ja) 循環腫瘍細胞を用いる転移性乳癌患者の療法中の各追跡期間ポイントでの無増悪および全生存を予測する方法
Slack et al. Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis
WO2006020936A2 (en) A method for assessing disease states by profile analysis of isolated circulating endothelial cells
Xie et al. Detection of circulating rare cells benefitted the diagnosis of malignant solitary pulmonary nodules
BR102020026395A2 (pt) Método, painel e kit para o diagnóstico e monitoramento do tratamento de pacientes com câncer de mama
HK1190457A (en) Steroid receptor assays for detecting tumor cells
HK1195121A (en) Steroid receptor assays for detecting tumor cells
HK1195121B (en) Steroid receptor assays for detecting tumor cells
HK1148348B (en) Automated enumeration and characterization of circulating melanoma cells in blood

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170118